Jazz Pharmaceuticals JAZZ Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxLiabilitiesNet.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's deferred tax assets?
- Jazz Pharmaceuticals (JAZZ) reported deferred tax assets of $547.7M in Q1 2026.
- How has Jazz Pharmaceuticals's deferred tax assets changed year-over-year?
- Jazz Pharmaceuticals's deferred tax assets decreased by 18.4% year-over-year, from $670.8M to $547.7M.
- What is the long-term trend for Jazz Pharmaceuticals's deferred tax assets?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's deferred tax assets has grown at a 35.4% compound annual growth rate (CAGR), from $130.4M to $594.5M.
- What does deferred tax assets mean?
- Future tax savings that the company expects to realize based on past losses or specific tax-deductible expenses.
- How do you interpret deferred tax assets?
- An increase suggests the company has accumulated tax credits or losses that may lower future tax payments, while a decrease indicates utilization of these benefits.
- How does deferred tax assets compare across companies?
- Common in R&D-heavy biotech firms; peers often show significant fluctuations based on clinical trial spending and tax planning.